About Us

Transforming Through Cellular Innovation

What We Do?

At CytoHub, our team brings together a rich blend of expertise, uniting traditional drug development and biopharmaceutical acumen with future-focused disciplines such as AI, Machine Learning, Cloud Computing and Smart Manufacturing. This multidisciplinary approach empowers us to drive our audacious mission forward: reinventing the process of cell and gene therapy drug, development and manufacturing for a healthier future.

Team

Rajib Biswas, PhD

Founder, CEO & Chairman

Satish Kumar

Lead AI/ML Engineer, BioEngineAI Platform

Frank Teoh

Vice President, Global Head of BioEngineAI Platform

Boyoon Choi, JD, MBA

General Counsel & Corporate Strategy

Matthieu Bauer, PhD

Senior Consultant, Cell Therapy

Erez Pery, PhD

Cell Based Assays

Stephanie Han, PhD

Cell Biology

Mudit Kakar, PhD, JD

Head, Intellectual Property & Strategy

Oscar J. Abilez, MD, PhD

CM Organoids

Advisors

David DiGiusto, PhD

Technical, Scientific, and Strategic Advisor

Prof. Vish Krishnan

Professor and Chair | UCSD

David H. Crean, PhD, MBA

Managing Partner | Cardiff Advisory LLC

Aitor Aguirre, PhD

Scientific Advisor at CytoHub, Inc. | Associate Professor of Biomedical Engineering at Michigan State University,

Our Mission

CytoHub is dedicated to revolutionizing the cell therapy landscape by developing innovative, efficient, and scalable solutions to produce high-quality cell therapy products. We are committed to overcoming the challenges faced by cell therapy developers through our customized process optimization and scaling techniques, underpinned by our novel BioEngineAI and BioEngineArray platforms, and developing biomanufacturing solutions.

Our mission is to co-develop cell-based products with Pharma, Biotech, and/or Academic partners, by enabling the efficient transition from research proof-of-concept to clinical manufacturing and control readiness.

Our Vision

Our vision is to revolutionize the landscape of cell therapy and regenerative medicine through innovative biomanufacturing solutions, i.e., “Crafting Cells for Cures”.